May 18, 2020 Acad, Gov/Utilities Lab Top-10 PAI Top-10

Thermo Fisher Scientific's Support of COVID-19 Response Continues to Expand with U.S. Government Contract for Products Used in Sample Collection

Thermo Fisher Scientific’s Support of COVID-19 Response Continues to Expand with U.S. Government Contract for Products Used in Sample Collection WALTHAM, Mass., May 18, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has received a contract from the U.S. government to provide highly specialized viral transport... Read more

May 14, 2020 Acad, Gov/Utilities Atomic Spectroscopy Lab Top-10

Helios 5 Laser PFIB Accelerates the Pace of Materials Research for Academic and Industrial Users

Helios 5 Laser PFIB Accelerates the Pace of Materials Research for Academic and Industrial Users First-of-its-kind commercial solution analyzes 3D and sub-surface data 15,000 times faster than a typical Ga-FIB HILLSBORO, Ore., May 14, 2020 /PRNewswire/ — Thermo Fisher Scientific today released the Thermo Scientific Helios 5 Laser PFIB system, an advanced focused ion beam... Read more

May 12, 2020 Acad, Gov/Utilities Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics

FDA Further Expands EUA for Thermo Fisher Scientific's COVID-19 Diagnostic Tests

Authorization brings more instruments on line, enables workflow flexibility and simplifies methods to increase throughput and allow more labs to run tests WALTHAM, Mass., May 12, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has further expanded emergency... Read more

May 5, 2020 Acad, Gov/Utilities Lab Top-10 Liq. Handling & Robotics PAI Top-10

FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies

WALTHAM, Mass.–(BUSINESS WIRE)–May 5, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical... Read more

May 3, 2020 Acad, Gov/Utilities PR/Corporate

Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

The serology test has a specificity greater than 99.8% and sensitivity of 100% (14 Days post-PCR confirmation) The high specificity of the test is crucial to determine reliably if a person has been exposed to the virus and if the patient has developed antibodies Roche will provide high double-digit millions of tests already in May... Read more

April 23, 2020 Acad, Gov/Utilities Microscopy

Microscopy Techniques for Energy Materials

WILEY ebook provides an overview of how microscopy can be applied in energy materials research. Download the ebook and read about: Microscopy techniques & their benefits for energy materials research Microscopy-enabled accomplishments in energy materials research (11 short versions of selected peer-reviewed articles from various WILEY journals) Current challenges & future developments in microscopy applications for energy materials (Interview with... Read more

April 21, 2020 Acad, Gov/Utilities Bio/Pharma/CRO Microscopy PAI Top-10 PR/Corporate

Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer

More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; expanding access helps reach more women2,3 cobas 6800/8800 Systems deliver full automation, helping laboratories meet the throughput and efficiencies that high-volume, HPV DNA screening programs require              Basel,... Read more

April 20, 2020 Acad, Gov/Utilities

US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time

Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary progressive multiple sclerosis, if approved Applications are based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the currently approved OCREVUS dosing regimen              Basel, 20 April 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more